Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESIGN: Dietary Sodium and Ertugliflozin in T2DM
NCT06983054Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of ertugliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Blood pressure at 7 months. Started Jul 2023; status: recruiting.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06983054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06983054.